LONA:NASDAQ
LeonaBio Inc
US$5.75
0.00%
(0.00) 1 天
10月9日, GMT-4 16:00:01 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 LONA 生成关键数据洞见…
开盘价
US$5.82
最高价
US$6.10
最低价
US$5.56
市值
5417.46万
平均成交量
34.17万
成交量
0.00
52 周最高价
US$14.19
52 周最低价
US$2.21
每股收益
-US$19.72
Beta 版
2.11
流通股数
942.20万
员工人数
19
开盘价
US$5.82
最高价
US$6.10
最低价
US$5.56
市值
5417.46万
平均成交量
34.17万
成交量
0.00
52 周最高价
US$14.19
52 周最低价
US$2.21
每股收益
-US$19.72
Beta 版
2.11
流通股数
942.20万
员工人数
19
新闻报道
来自网络来源和新闻合作伙伴
www.tmgm.com
·
2小时前
标普500：盈利强劲抵消收益率逆风——HSBC
Traders Union
·
14小时前
Ryan Detrick指出，S&P 500自2019年以来的涨幅主要由盈利和股息推动
www.me.news
·
3小时前
大摩研报解读：标普等权重跌 5%，AI 集中度风险在年末前积累
资料
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
LeonaBio Inc简介